Anna Malykhina
Concepts (300)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder | 34 | 2025 | 195 | 7.670 |
Why?
| | Lower Urinary Tract Symptoms | 11 | 2022 | 62 | 3.860 |
Why?
| | Potassium Channels, Tandem Pore Domain | 5 | 2024 | 14 | 2.890 |
Why?
| | Urination | 12 | 2025 | 47 | 2.830 |
Why?
| | Muscle Contraction | 15 | 2025 | 429 | 2.640 |
Why?
| | Muscle, Smooth | 11 | 2025 | 153 | 2.630 |
Why?
| | Urinary Bladder, Overactive | 10 | 2021 | 23 | 2.450 |
Why?
| | Pelvic Pain | 4 | 2024 | 42 | 2.200 |
Why?
| | Urinary Bladder, Neurogenic | 4 | 2022 | 46 | 1.670 |
Why?
| | Multiple Sclerosis | 6 | 2022 | 489 | 1.430 |
Why?
| | TRPV Cation Channels | 6 | 2021 | 43 | 1.350 |
Why?
| | Colon | 7 | 2014 | 309 | 1.310 |
Why?
| | Cystitis, Interstitial | 6 | 2021 | 20 | 1.250 |
Why?
| | Coronavirus Infections | 3 | 2022 | 383 | 1.210 |
Why?
| | Gastrointestinal Diseases | 2 | 2024 | 221 | 1.120 |
Why?
| | Chronic Pain | 2 | 2024 | 291 | 1.110 |
Why?
| | Sensory Receptor Cells | 3 | 2022 | 98 | 1.080 |
Why?
| | Urinary Bladder Diseases | 5 | 2019 | 18 | 1.070 |
Why?
| | Erectile Dysfunction | 2 | 2021 | 38 | 1.030 |
Why?
| | Protein Kinase C | 3 | 2015 | 251 | 0.910 |
Why?
| | Murine hepatitis virus | 3 | 2022 | 16 | 0.890 |
Why?
| | Hypertrophy | 3 | 2024 | 128 | 0.870 |
Why?
| | Ganglia, Spinal | 7 | 2025 | 88 | 0.830 |
Why?
| | Urinary Bladder Neck Obstruction | 4 | 2023 | 19 | 0.810 |
Why?
| | Colitis | 7 | 2014 | 280 | 0.760 |
Why?
| | Mice, Inbred C57BL | 15 | 2025 | 5983 | 0.760 |
Why?
| | Lumbosacral Region | 2 | 2025 | 59 | 0.750 |
Why?
| | Animals | 42 | 2025 | 38030 | 0.740 |
Why?
| | Pain Perception | 1 | 2022 | 24 | 0.700 |
Why?
| | Administration, Intravesical | 3 | 2017 | 17 | 0.660 |
Why?
| | Receptor, Muscarinic M3 | 1 | 2020 | 3 | 0.650 |
Why?
| | Receptor, Adenosine A1 | 1 | 2020 | 11 | 0.650 |
Why?
| | Prostatic Hyperplasia | 1 | 2021 | 40 | 0.640 |
Why?
| | Nociception | 1 | 2020 | 17 | 0.640 |
Why?
| | Urinary Tract Infections | 2 | 2014 | 210 | 0.640 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2020 | 19 | 0.640 |
Why?
| | Mice, Knockout | 3 | 2024 | 3124 | 0.640 |
Why?
| | Substance P | 4 | 2016 | 38 | 0.630 |
Why?
| | Calcitonin Gene-Related Peptide | 4 | 2016 | 40 | 0.630 |
Why?
| | Neuronal Plasticity | 2 | 2013 | 305 | 0.620 |
Why?
| | Analgesics | 1 | 2022 | 231 | 0.610 |
Why?
| | Coronavirus | 3 | 2022 | 47 | 0.600 |
Why?
| | Hyperalgesia | 1 | 2020 | 127 | 0.600 |
Why?
| | Neuroglia | 1 | 2020 | 173 | 0.590 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2019 | 69 | 0.580 |
Why?
| | Mice | 22 | 2025 | 18329 | 0.570 |
Why?
| | Urodynamics | 6 | 2025 | 44 | 0.560 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2022 | 552 | 0.520 |
Why?
| | Marijuana Smoking | 1 | 2021 | 249 | 0.520 |
Why?
| | Urethra | 1 | 2017 | 56 | 0.510 |
Why?
| | Inflammation | 5 | 2020 | 2878 | 0.500 |
Why?
| | Urogenital System | 1 | 2016 | 16 | 0.480 |
Why?
| | Urinary Tract | 1 | 2016 | 47 | 0.470 |
Why?
| | Diterpenes | 2 | 2012 | 26 | 0.460 |
Why?
| | Phenotype | 3 | 2019 | 3155 | 0.440 |
Why?
| | Cannabinoids | 1 | 2017 | 184 | 0.440 |
Why?
| | Male | 36 | 2025 | 72842 | 0.440 |
Why?
| | Disease Models, Animal | 14 | 2025 | 4560 | 0.420 |
Why?
| | Encephalomyelitis | 1 | 2014 | 14 | 0.420 |
Why?
| | Cystitis | 1 | 2014 | 24 | 0.420 |
Why?
| | Estrous Cycle | 1 | 2014 | 22 | 0.410 |
Why?
| | Rats, Sprague-Dawley | 9 | 2015 | 2524 | 0.410 |
Why?
| | Neuropeptides | 1 | 2014 | 75 | 0.410 |
Why?
| | Vincristine | 3 | 2024 | 142 | 0.410 |
Why?
| | Demyelinating Diseases | 1 | 2014 | 84 | 0.400 |
Why?
| | Marijuana Use | 1 | 2017 | 222 | 0.390 |
Why?
| | Neurons | 4 | 2013 | 1649 | 0.390 |
Why?
| | Cyclic Nucleotide-Gated Cation Channels | 2 | 2010 | 15 | 0.390 |
Why?
| | Penis | 1 | 2013 | 33 | 0.380 |
Why?
| | Viscera | 1 | 2012 | 17 | 0.380 |
Why?
| | Peripheral Nerves | 1 | 2012 | 72 | 0.370 |
Why?
| | Neural Pathways | 1 | 2014 | 313 | 0.370 |
Why?
| | Colonic Diseases | 1 | 2012 | 37 | 0.350 |
Why?
| | Depression | 2 | 2021 | 1546 | 0.350 |
Why?
| | Trinitrobenzenesulfonic Acid | 5 | 2012 | 10 | 0.340 |
Why?
| | Rats | 9 | 2014 | 5584 | 0.330 |
Why?
| | Motor Neurons | 1 | 2012 | 236 | 0.320 |
Why?
| | Color Vision Defects | 1 | 2010 | 8 | 0.310 |
Why?
| | Urologic Diseases | 2 | 2024 | 42 | 0.310 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2010 | 20 | 0.310 |
Why?
| | Biomarkers | 5 | 2021 | 4295 | 0.300 |
Why?
| | Protein Subunits | 1 | 2010 | 229 | 0.290 |
Why?
| | Gene Expression Profiling | 3 | 2025 | 1767 | 0.280 |
Why?
| | Female | 26 | 2025 | 78844 | 0.270 |
Why?
| | Doxorubicin | 2 | 2021 | 401 | 0.270 |
Why?
| | Calcium Channels | 3 | 2021 | 157 | 0.260 |
Why?
| | Humans | 32 | 2024 | 145474 | 0.260 |
Why?
| | Pons | 2 | 2017 | 33 | 0.250 |
Why?
| | Central Nervous System | 2 | 2022 | 282 | 0.250 |
Why?
| | Brain-Derived Neurotrophic Factor | 3 | 2021 | 154 | 0.240 |
Why?
| | Lactams, Macrocyclic | 2 | 2017 | 51 | 0.240 |
Why?
| | Benzoquinones | 2 | 2017 | 46 | 0.240 |
Why?
| | Age Factors | 5 | 2024 | 3342 | 0.240 |
Why?
| | Mice, Transgenic | 3 | 2022 | 2188 | 0.240 |
Why?
| | Visceral Pain | 1 | 2025 | 3 | 0.230 |
Why?
| | Cystostomy | 1 | 2025 | 11 | 0.230 |
Why?
| | Sodium Channels | 1 | 2004 | 63 | 0.210 |
Why?
| | Channelopathies | 1 | 2004 | 5 | 0.200 |
Why?
| | Nerve Growth Factor | 3 | 2021 | 36 | 0.200 |
Why?
| | Mutation | 3 | 2010 | 4075 | 0.200 |
Why?
| | Catastrophization | 2 | 2021 | 16 | 0.200 |
Why?
| | Physical Stimulation | 2 | 2014 | 68 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 848 | 0.190 |
Why?
| | Tocotrienols | 1 | 2023 | 3 | 0.190 |
Why?
| | Receptors, Muscarinic | 2 | 2018 | 20 | 0.190 |
Why?
| | Colitis, Ulcerative | 1 | 2004 | 148 | 0.190 |
Why?
| | Muscarinic Agonists | 2 | 2020 | 14 | 0.190 |
Why?
| | Sialic Acid Binding Ig-like Lectin 1 | 1 | 2022 | 11 | 0.190 |
Why?
| | Signal Transduction | 7 | 2025 | 5216 | 0.190 |
Why?
| | Fluorescent Antibody Technique | 2 | 2022 | 365 | 0.180 |
Why?
| | Gastrointestinal Tract | 1 | 2004 | 204 | 0.170 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2378 | 0.170 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2022 | 337 | 0.170 |
Why?
| | Electric Stimulation | 4 | 2012 | 276 | 0.160 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2021 | 18 | 0.160 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 134 | 0.160 |
Why?
| | Benzilates | 1 | 2020 | 1 | 0.160 |
Why?
| | Nortropanes | 1 | 2020 | 1 | 0.160 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 2020 | 10 | 0.160 |
Why?
| | Purinergic P1 Receptor Agonists | 1 | 2020 | 7 | 0.160 |
Why?
| | Genes, Synthetic | 1 | 2020 | 13 | 0.160 |
Why?
| | Freund's Adjuvant | 1 | 2020 | 18 | 0.160 |
Why?
| | Xanthines | 1 | 2020 | 23 | 0.160 |
Why?
| | Clozapine | 1 | 2020 | 20 | 0.160 |
Why?
| | Theophylline | 1 | 2020 | 41 | 0.160 |
Why?
| | Touch | 1 | 2020 | 39 | 0.160 |
Why?
| | Sex Characteristics | 1 | 2025 | 782 | 0.150 |
Why?
| | Constipation | 1 | 2021 | 98 | 0.150 |
Why?
| | Smooth Muscle Myosins | 1 | 2019 | 7 | 0.150 |
Why?
| | Muscle Relaxation | 1 | 2019 | 28 | 0.150 |
Why?
| | Myosin Light Chains | 1 | 2019 | 28 | 0.150 |
Why?
| | Comorbidity | 2 | 2016 | 1661 | 0.150 |
Why?
| | Transcriptome | 1 | 2025 | 1038 | 0.140 |
Why?
| | Neurons, Afferent | 2 | 2012 | 102 | 0.140 |
Why?
| | Gene Frequency | 2 | 2018 | 487 | 0.140 |
Why?
| | RNA-Binding Proteins | 1 | 2022 | 447 | 0.140 |
Why?
| | Receptors, Purinergic P2X1 | 1 | 2018 | 3 | 0.140 |
Why?
| | Cholinergic Fibers | 1 | 2018 | 19 | 0.140 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2020 | 231 | 0.140 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 140 | 0.140 |
Why?
| | Spinal Cord | 2 | 2014 | 382 | 0.130 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2019 | 376 | 0.130 |
Why?
| | Recombinant Fusion Proteins | 1 | 2020 | 666 | 0.130 |
Why?
| | White Matter | 1 | 2019 | 153 | 0.130 |
Why?
| | Caveolins | 1 | 2017 | 5 | 0.130 |
Why?
| | Hot Temperature | 1 | 2020 | 396 | 0.130 |
Why?
| | Severity of Illness Index | 4 | 2021 | 2930 | 0.130 |
Why?
| | Urinary Incontinence, Urge | 1 | 2017 | 2 | 0.130 |
Why?
| | Brain Stem | 1 | 2017 | 98 | 0.130 |
Why?
| | Lumbosacral Plexus | 2 | 2017 | 10 | 0.130 |
Why?
| | Ion Channel Gating | 2 | 2010 | 94 | 0.130 |
Why?
| | Postmenopause | 2 | 2016 | 392 | 0.120 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2017 | 23 | 0.120 |
Why?
| | Reflex | 2 | 2018 | 70 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2024 | 2028 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2021 | 337 | 0.120 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 59 | 0.120 |
Why?
| | Cytoskeleton | 1 | 2017 | 192 | 0.120 |
Why?
| | Polymorphism, Genetic | 1 | 2018 | 614 | 0.120 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 1246 | 0.110 |
Why?
| | Phorbol 12,13-Dibutyrate | 1 | 2015 | 8 | 0.110 |
Why?
| | Phorbol Esters | 1 | 2015 | 13 | 0.110 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 450 | 0.110 |
Why?
| | Sex Factors | 2 | 2024 | 2105 | 0.110 |
Why?
| | Pilot Projects | 2 | 2019 | 1891 | 0.110 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2017 | 270 | 0.110 |
Why?
| | Down-Regulation | 1 | 2017 | 618 | 0.110 |
Why?
| | RNA, Small Interfering | 1 | 2017 | 637 | 0.110 |
Why?
| | Pituitary-Adrenal System | 1 | 2016 | 164 | 0.110 |
Why?
| | Pyuria | 1 | 2014 | 5 | 0.110 |
Why?
| | Brain Diseases | 1 | 2016 | 155 | 0.110 |
Why?
| | Bacteriuria | 1 | 2014 | 12 | 0.100 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2016 | 199 | 0.100 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1716 | 0.100 |
Why?
| | Carbachol | 2 | 2011 | 17 | 0.100 |
Why?
| | Nerve Growth Factors | 1 | 2014 | 78 | 0.100 |
Why?
| | Time Factors | 3 | 2021 | 7123 | 0.100 |
Why?
| | Peroxidase | 1 | 2014 | 168 | 0.100 |
Why?
| | Alcohol Drinking | 1 | 2021 | 837 | 0.100 |
Why?
| | Genotype | 1 | 2018 | 1852 | 0.100 |
Why?
| | Potassium Channels | 1 | 2014 | 147 | 0.100 |
Why?
| | Aging | 1 | 2024 | 1969 | 0.100 |
Why?
| | Voltage-Gated Sodium Channels | 1 | 2012 | 5 | 0.100 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channels | 1 | 2012 | 11 | 0.100 |
Why?
| | Afferent Pathways | 1 | 2013 | 46 | 0.100 |
Why?
| | Cholinergic Neurons | 1 | 2012 | 18 | 0.090 |
Why?
| | Blotting, Western | 2 | 2012 | 1179 | 0.090 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 143 | 0.090 |
Why?
| | Adult | 8 | 2021 | 40777 | 0.090 |
Why?
| | Organ Culture Techniques | 1 | 2013 | 154 | 0.090 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1048 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2019 | 3623 | 0.090 |
Why?
| | Cytokines | 1 | 2019 | 2067 | 0.090 |
Why?
| | Prospective Studies | 6 | 2021 | 8057 | 0.080 |
Why?
| | Cholinergic Agents | 1 | 2011 | 18 | 0.080 |
Why?
| | Premenopause | 1 | 2011 | 125 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 2158 | 0.080 |
Why?
| | Data Interpretation, Statistical | 1 | 2012 | 368 | 0.080 |
Why?
| | Proteomics | 1 | 2017 | 1188 | 0.080 |
Why?
| | Neuralgia | 1 | 2011 | 140 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5423 | 0.080 |
Why?
| | Mutant Proteins | 1 | 2010 | 105 | 0.080 |
Why?
| | Models, Animal | 1 | 2011 | 393 | 0.070 |
Why?
| | Incidence | 1 | 2016 | 2923 | 0.070 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 302 | 0.070 |
Why?
| | Recurrence | 1 | 2011 | 1138 | 0.070 |
Why?
| | Protein Transport | 1 | 2010 | 442 | 0.070 |
Why?
| | Middle Aged | 8 | 2021 | 36215 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 977 | 0.070 |
Why?
| | Dextran Sulfate | 2 | 2005 | 93 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2012 | 740 | 0.070 |
Why?
| | Acute Disease | 1 | 2011 | 1036 | 0.070 |
Why?
| | Stress, Psychological | 1 | 2016 | 1146 | 0.060 |
Why?
| | Prognosis | 1 | 2016 | 4316 | 0.060 |
Why?
| | src-Family Kinases | 2 | 2007 | 92 | 0.060 |
Why?
| | Quality of Life | 3 | 2021 | 3204 | 0.060 |
Why?
| | HEK293 Cells | 1 | 2010 | 741 | 0.060 |
Why?
| | Brain | 1 | 2019 | 2947 | 0.060 |
Why?
| | Trinucleotide Repeats | 1 | 2006 | 31 | 0.060 |
Why?
| | Trinucleotide Repeat Expansion | 1 | 2006 | 43 | 0.060 |
Why?
| | Tyrosine | 1 | 2007 | 217 | 0.060 |
Why?
| | Irritable Bowel Syndrome | 1 | 2006 | 29 | 0.060 |
Why?
| | Iron-Binding Proteins | 1 | 2006 | 43 | 0.060 |
Why?
| | Risk Assessment | 1 | 2016 | 3747 | 0.060 |
Why?
| | Neoplasms | 1 | 2021 | 2906 | 0.060 |
Why?
| | Sacrum | 1 | 2005 | 80 | 0.060 |
Why?
| | Sodium Channel Blockers | 1 | 2004 | 23 | 0.050 |
Why?
| | Carbocyanines | 1 | 2004 | 37 | 0.050 |
Why?
| | Capsaicin | 1 | 2004 | 30 | 0.050 |
Why?
| | Tetrodotoxin | 1 | 2004 | 40 | 0.050 |
Why?
| | Cerebellum | 1 | 2006 | 224 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2007 | 431 | 0.050 |
Why?
| | Membrane Potentials | 1 | 2004 | 278 | 0.050 |
Why?
| | Patch-Clamp Techniques | 1 | 2004 | 289 | 0.050 |
Why?
| | Lumbar Vertebrae | 1 | 2005 | 252 | 0.050 |
Why?
| | Drug Interactions | 1 | 2004 | 405 | 0.050 |
Why?
| | Electrophysiology | 3 | 2010 | 218 | 0.050 |
Why?
| | Ion Channels | 1 | 2004 | 129 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2024 | 178 | 0.050 |
Why?
| | Action Potentials | 1 | 2006 | 502 | 0.050 |
Why?
| | Mast Cells | 1 | 2024 | 147 | 0.050 |
Why?
| | Aged | 4 | 2017 | 26153 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2010 | 2803 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2019 | 1261 | 0.040 |
Why?
| | Models, Biological | 2 | 2010 | 1764 | 0.040 |
Why?
| | Osteopontin | 1 | 2021 | 35 | 0.040 |
Why?
| | Visual Analog Scale | 1 | 2021 | 34 | 0.040 |
Why?
| | Child, Preschool | 1 | 2016 | 11853 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5904 | 0.040 |
Why?
| | Interleukin-2 | 1 | 2022 | 440 | 0.040 |
Why?
| | Child | 2 | 2021 | 22707 | 0.040 |
Why?
| | Administration, Oral | 1 | 2023 | 866 | 0.040 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2019 | 19 | 0.040 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2019 | 8 | 0.040 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2019 | 10 | 0.040 |
Why?
| | Anxiety, Separation | 1 | 2018 | 11 | 0.040 |
Why?
| | Maternal Deprivation | 1 | 2018 | 16 | 0.040 |
Why?
| | Risk Factors | 1 | 2011 | 10885 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2004 | 4148 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2018 | 891 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3904 | 0.030 |
Why?
| | Bethanechol | 1 | 2014 | 3 | 0.030 |
Why?
| | Atropine | 1 | 2014 | 37 | 0.030 |
Why?
| | Phosphorylation | 1 | 2019 | 1707 | 0.030 |
Why?
| | Muscarinic Antagonists | 1 | 2014 | 30 | 0.030 |
Why?
| | Young Adult | 1 | 2011 | 14218 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2016 | 298 | 0.030 |
Why?
| | Health Surveys | 1 | 2016 | 518 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2011 | 17291 | 0.020 |
Why?
| | Phenanthrenes | 1 | 2012 | 12 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2016 | 6066 | 0.020 |
Why?
| | Carboxylic Acids | 1 | 2012 | 31 | 0.020 |
Why?
| | Calcium | 2 | 2010 | 1190 | 0.020 |
Why?
| | Adolescent | 1 | 2011 | 22529 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2014 | 500 | 0.020 |
Why?
| | Heart Rate | 1 | 2016 | 855 | 0.020 |
Why?
| | Intestinal Diseases | 1 | 2011 | 43 | 0.020 |
Why?
| | Rabbits | 1 | 2012 | 652 | 0.020 |
Why?
| | Benzimidazoles | 1 | 2012 | 189 | 0.020 |
Why?
| | Adaptation, Psychological | 1 | 2016 | 716 | 0.020 |
Why?
| | Circular Dichroism | 1 | 2010 | 151 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 331 | 0.020 |
Why?
| | Protein Stability | 1 | 2010 | 176 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 820 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2010 | 371 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 319 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2010 | 563 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 1118 | 0.020 |
Why?
| | Cholinergic Agonists | 1 | 2007 | 8 | 0.020 |
Why?
| | Potassium Chloride | 1 | 2007 | 40 | 0.020 |
Why?
| | Nitric Acid | 1 | 2007 | 2 | 0.020 |
Why?
| | Enema | 1 | 2007 | 46 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2007 | 128 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1368 | 0.020 |
Why?
| | Escherichia coli | 1 | 2010 | 835 | 0.010 |
Why?
| | Friedreich Ataxia | 1 | 2006 | 78 | 0.010 |
Why?
| | Cell Line | 1 | 2010 | 2823 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8333 | 0.010 |
Why?
| | Alleles | 1 | 2006 | 894 | 0.010 |
Why?
| | Recovery of Function | 1 | 2007 | 716 | 0.010 |
Why?
|
|
Malykhina's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|